Salarius Pharmaceuticals, INC 8-K filings

Decoy Therapeutics Inc. held its 2026 Annual Meeting of Stockholders, re-electing directors, approving executive compensation, and ratifying auditor appointment.

Decoy Therapeutics Inc. announced a private placement financing expected to yield approximately $3.5 million in gross proceeds to advance its lead asset into clinical trials.

Decoy Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held on July 14, 2026, with specific deadlines for shareholder proposals and director nominations.

Decoy Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.

Decoy Therapeutics Inc. announced a 1-for-12 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Decoy Therapeutics Inc. stockholders approved a reverse stock split and a new equity incentive plan at a virtual special meeting held on February 24, 2026.

Salarius Pharmaceuticals, Inc. has officially changed its corporate name to Decoy Therapeutics Inc. and its Nasdaq ticker symbol to DCOY, signaling a strategic pivot to next-generation peptide-conjugate therapeutics.

Salarius Pharmaceuticals, Inc. received a delisting notice from Nasdaq due to its common stock falling below the minimum bid price requirement, with an appeal planned.

Salarius Pharmaceuticals, Inc. announced the results of its reconvened 2025 Annual Meeting of Stockholders, confirming the re-election of two Class I directors, approval of executive compensation, and ratification of its independent auditor.

Salarius Pharmaceuticals adjourned its 2025 Annual Meeting of Stockholders due to insufficient quorum, rescheduling it for December 31, 2025.

Salarius Pharmaceuticals, Inc. announced the appointment of Frederick E. Pierce as CEO, Dr. Barbara Hibner as CSO, and Peter Marschel as CBO, effective upon the closing of a previously announced merger.

Salarius Pharmaceuticals, Inc. issued an 8-K filing to correct inaccurate reports of its delisting from the Nasdaq Capital Market, confirming its continued listing and trading.

Salarius Pharmaceuticals completed its merger with Decoy Therapeutics and raised approximately $6.3 million in net proceeds from a public offering of common stock and warrants to fund clinical development and general corporate purposes.

Salarius Pharmaceuticals' Board of Directors approved a $225,000 cash transaction bonus for Acting CEO Mark J. Rosenblum, contingent on the closing of the Decoy Therapeutics merger.

Salarius Pharmaceuticals announced it has regained full compliance with Nasdaq listing requirements, a critical step towards its planned merger with Decoy Therapeutics.

Salarius Pharmaceuticals, Inc. announced it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement after raising $6.2 million through recent stock sales.

Salarius Pharmaceuticals modified its merger agreement with Decoy Therapeutics, adjusting preferred stock conversion terms with a new baseline price and a $3.75 per share floor for dilutive financings.

Salarius Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price requirement while continuing to work towards compliance with the Equity Standard, as its merger with Decoy Therapeutics advances.

Salarius Pharmaceuticals, Inc. received an extension from Nasdaq to regain compliance with its Equity Standard by October 20, 2025, following a recent reverse stock split.

Salarius Pharmaceuticals filed a prospectus supplement to offer up to $2.6 million in common stock through an at-the-market facility.

Salarius Pharmaceuticals filed an amendment to its merger agreement with Decoy Therapeutics, correcting pro forma financials and detailing revised ownership and financing terms.

Salarius Pharmaceuticals provides an update on its merger with Decoy Therapeutics, detailing the new combined entity's strategic pipeline and financial adjustments, while facing ongoing Nasdaq listing compliance issues.

Salarius Pharmaceuticals, Inc. announced the appointment of Mark J. Rosenblum as acting Chief Executive Officer following the resignation of David J. Arthur.

Salarius Pharmaceuticals will effect a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Salarius Pharmaceuticals, Inc. anticipates a $900,000 net loss for Q2 2025 and has raised $3.8 million through an equity line to bolster its cash position to $4.5 million.

Salarius Pharmaceuticals, Inc. has entered into a Fourth Amendment to its merger agreement with Decoy Therapeutics Inc., modifying preferred stock conversion terms to secure holder consent and facilitate the merger.

Salarius Pharmaceuticals, Inc. has received an additional extension from the Nasdaq Hearings Panel to regain compliance with both the Equity Standard and Minimum Bid Price Requirement by mid to late August 2025.

Salarius Pharmaceuticals, Inc. has entered into a Third Amendment to its merger agreement with Decoy Therapeutics Inc., allowing Decoy's promissory note holders to convert their debt into newly created Series B Non-Voting Convertible Preferred Stock.

Salarius Pharmaceuticals has received an additional extension from Nasdaq to regain compliance with listing standards, while progressing its definitive merger with preclinical biopharmaceutical company Decoy Therapeutics.

Salarius Pharmaceuticals, Inc. stockholders approved a reverse stock split and the issuance of common stock to comply with Nasdaq listing rules at a special meeting held on July 8, 2025.